Merck’s CAPVAXIVE Wins FDA Approval for High-Risk Children
RAHWAY, N.J., June 18, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has approved an expanded...
CAPVAXIVE
Advertisement
Merck’s CAPVAXIVE Shows Strong Immune Response in Children
RAHWAY, N.J. – September 11, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada,...
Advertisement
